AndrewStaurtKoenigDO

PubMed

• 30 citations
  Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active...
  Josef S Smolen, Annette Szumski, Andrew S Koenig, Thomas V. Jones, Lisa Marshall
  Arthritis Research & Therapy. 2018-01-16
• 7 citations
  Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
  George W. Reed, David H. Collier, Andrew S Koenig, Katherine C. Saunders, Dimitrios A. Pappas
  Arthritis Research & Therapy. 2017-04-27
• 44 citations
  Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity
  Josef S Smolen, Vibeke Strand, Andrew S Koenig, Annette Szumski, Sameer Kotak
  Arthritis Research & Therapy. 2016-05-21

Journal Articles

• Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: Pooled analysis from large randomized clinical trials  
  Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E, J Rheumatol, 1/1/2015
• Impact of etanercept therapy on disease activity and health-related quality of life in moderate rheumatoid arthritis patients: population from a national British obser...  
  Kotak S, Mardekian J, Horowicz-Mehler N, Shah A, Burgess A, Kim J, Gemmen E, Boyd H, Koenig A, Value in Health, 1/1/2015
• Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia  
  Pavelka K, Burgos-Vargas R, Miranda P, Guzman R, Yen J, Al Izzi M, Szekanecz A, Tang B, Szumski A, Kotak S, Bananis E, Koenig AS, Mahgoub E, & Rahman M, Int. J. Clin. Rheumatol, 1/1/2014
• When to Adjust Therapy in Patients with Rheumatoid Arthritis After Initiation of Etanercept plus Methotrexate or Methotrexate Alone: Findings from a Randomized Study (...  
  When to Adjust Therapy in Patients with Rheumatoid Arthritis After Initiation of Etanercept plus Methotrexate or Methotrexate Alone: Findings from a Randomized Study (..., J Rheumatol, 1/1/2014
• Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis  
  Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E, Rheumatology, 1/1/2014
• Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial  
  Husni E, Qureshi A, Koenig A, Pedersen R, Robertson D, J Dermatolog Treat, 1/20/2013
• Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methot...  
  Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, Ferdousi T, Koenig AS, Kotak S, Vlahos B, J Clin Rheumatol, 1/18/2013
• Maintenance, Reduction or Withdrawal of Etanercept: A Randomized Controlled Trial in Moderate Rheumatoid Arthritis Patients Achieving Low Disease Activity With Etanerc...  
  Smolen J, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig A, Vlahos B, Lancet, 1/16/2013
• Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment  
  Puig L; Strohal R; Fuiman J; Pedersen R; Szumski A; Koenig A; Robertson D; Drexel H, Journal of Dermatological, 1/13/2013
• Health Outcomes Comparison between Etanercept and Usual DMARD Therapy in an Asia-Pacific Population with Rheumatoid Arthritis  
  Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig A, Vlahos B, Pedersen R, Singh A, BMC Musculoskelet Disord, 1/8/2013
• Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs controls from clinical trials i...  
  Heijde DV, Zack D, Wajdula J, Sridharan S, Koenig A, Scand J Rheumatol, 1/1/2013
• Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience  
  Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC, 1/1/2013
• Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort  
  Markenson JA, Koenig AS, Feng JY, Chaudhari S, Zack DJ, Collier D, Weaver A, J Clin Rheumatol, 1/1/2013
• Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1  
  Weaver A, Troum O, Hooper M, Koenig AS, Chaudhari S, Feng J, Wenkert D, J Rheumatol, 1/1/2013
• Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy  
  Hammoudeh M, Zack DJ, Li WZ, Stewart VM, Koenig AS, J INT MED RES, 1/1/2013
• Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis  
  Bae S, Gun S, Mok CC, Khandker R, Nab H, Koenig AS, Vlahos B, Pedersen R and Singh A, BMC Musculoskeletal Disorders, 1/1/2013
• Comparison of Health-Related Quality of Life in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis and Effects of Etanercept Treatment  
  Strand V,Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D, Ann Rheum Dis, 1/17/2012
• Clinical Efficacy of Etanercept Versus Sulfasalazine in Ankylosing Spondylitis Subjects with Peripheral Joint Involvement  
  Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, Koenig AS, J Rheumatol, 1/15/2012
• Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years):...  
  Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS, Ann Rheum Dis, 1/8/2012
• Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients treated with etanercept or sulfasalazine in the ASCEND ...  
  van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS, Rheumatology, 1/1/2012
• When is switching warranted among biologic therapies in rheumatoid arthritis?  
  Reynolds A, Koenig AS, Bananis S, Singh A, Exp Rev Pharmaco Outcomes Res, 1/1/2012
• Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial  
  Kim H, Hsu P, Barba M, Sulaiman W, Robertson D, Vlahos B, Khandker R, Nab H, Freundlich B, Koenig AS, International Journal of Rheumatic Diseases, 1/1/2012
• Two-year clinical and radiographic results with combination Etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind,...  
  Emery P., Breedveld F., Van Der Heijde D., Ferraccioli G., Dougados M., Robertson D., Pedersen R., Koenig A.S., Freundlich B, Art & Rheum, 1/1/2010
• Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind,...  
  Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Fougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B, Arthritis and Rheumatism, 1/1/2010
• Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the...  
  Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R, Annals of the Rheumatic Diseases, 1/1/2010
• Join now to see all

Abstracts/Posters

• The role of c-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis
  Baraliakos X, Szumski A, Koenig A, Jones H;, EULAR, European League Against Rheumatism, 1/1/2015
• Early experience with tofacitinib: patient characteristics and treatment patterns in two healthcare claims databases
  Harnett J, Curtis JR, Gerber R, Gruben D, Koenig A, Journal of Managed Care & Specialty Pharmacy, 1/1/2015
• One-year treatment patterns and healthcare resource use among patients with rheumatoid arthritis newly initiating treatment with biologic DMARDs
  Harnett J, Gerber R, Gruben D, Wiederkehr D, Mahgoub EY, Wallenstein G, Koenig A, Journal of Managed Care & Specialty Pharmacy, 1/1/2015
• Patient Preferences Associated with Therapies for Rheumatoid Arthritis among Humana Medicare Members: a Conjoint Analysis
  Louder AM, Singh A, Cappelleri JC, Koenig A, Aten A, Saverno K, Pasquale MK, Journal of Managed Care & Specialty Pharmacy, 1/1/2015
• C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis
  Baraliakos X, Szumski A, Koenig A, Jones H, Clin Exp Rheumatol, 1/1/2014
• Efficacy and safety of tofacitinib in patients with rheumatoid arthritis that had inadequate response to non-biologic DMARDs or one or more biologic DMARDs including t...
  Charles-Schoeman C, Burmester G, Koenig A, Maurey J, Naik S, Bourret J, Kwok K, Bananis E, Fleischmann R, Pharmacotherapy, 1/1/2014
• Evaluation of Tumor Necrosis Factor Inhibitor (TNFi) Utilization Patterns, Concomitant Conventional DMARD (cDMARD) Therapy, and Associated Costs for RA-Related Healthc...
  Harnett J, Gerber RA, Wiederkehr D, Koenig A, Gruben D, J Manag Care Pharm, 1/1/2014
• Evaluation of Tumor Necrosis Factor Inhibitor (TNFi) Utilization Patterns, Concomitant Conventional DMARD (cDMARD) Therapy, and Associated Costs for RA-Related Healthc...
  Gerber RA, Wiederkehr D, Gruben D, Koenig A, Harnett J, Academy of Managed Care Pharmacy - 2nd Nexus Conference, 1/1/2014
• Efficacy and safety of tofacitinib in patients with rheumatoid arthritis had inadequate response to nonbiologic DMARDs or one or more biologic DMARDs including TNF inh...
  Charles-Schoeman, Burmester G, Koenig A, Maurey J, Naik S, Bourret J, Kwok K, Bananis S, Fleischmann R, Journal of Managed Care & Speciality Pharmacy (JMCP), 1/1/2014
• Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after Food and Drug Administration Approval: results fr...
  Kavanaugh A, Reed GW, Saunders KC, Koenig AS, Geier J, Kremer JM, Greenberg JD, Bingham III CO, Arthritis Rheum, 1/1/2014
• Evaluation of biologic treatment patterns, clinical outcomes, and healthcare resource utilization post-tumor necrosis factor inhibitor discontinuation in rheumatoid ar...
  Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J, Arthritis Rheum, 1/1/2014
• Evaluation of Real World Experience with Non-biologic DMARDs in the Treatment of RA: Data from an Electronic Health Record Database
  Wiederkehr D, Harnett J, Gerber R, Gruben D, Mahgoub E, Wallenstein G, Koenig A, Arthritis Rheum, 1/1/2014
• Understanding patient preferences associated with the use of therapies for rheumatoid arthritis: results of conjoint analysis
  Saverno K, Louder A, Singh A, Cappelleri J, Aten A, Koenig A, Pasquale M, Arthritis Rheum, 1/1/2014
• Evaluation of real world experience with non-biologic DMARD in the treatment of RA: data from an electronic health record database
  Wiederkehr D, Harnett J, Gerber R, Gruben D, Mahgoub EY, Wallenstein G, Koenig A, Arthritis Rheum, 1/1/2014
• Primary non-adherence, associated clinical outcomes and healthcare resource utilization among rheumatoid arthritis patients prescribed injectable biologics
  Harnett J, Wiederkehr D, Gerber R, Gruben D, Bourret J, Koenig A, Arthritis Rheum, 1/1/2014
• Basal metabolic rate as an indicator of Rheumatoid Arthris disease activity and predictor of remission: Australian results from period 1 of the Preserve trail
  Buchanan R, Will R, Koenig A, Szumski A, Jones H, Thirunavukkarasu K, Witcombe D, Intern Med J, 1/1/2013
• Relationship between clinical response and radiographic outcomes in patients with moderate Rheumatoid Arthritis in the Preserve trial
  Bananis E, Smolen J, Van Vollenhoven R, Pederson R, Szumski A, Koenig A, Intern Med J, 1/1/2013
• Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
  Cohen SB, Fleischmann RM, Kremer JM, Koenig A, Kwok K, Wang L, Mebus CA, Riese R, Robinson T, Arthritis & Rheumatism, 1/1/2013
• Impact of etanercept-methotrexate therapy on patient-reported outcomes in a randomized controlled trial in moderately active rheumatoid arthritis patients
  P. Bird, J. Wollenhaup, S.-H. Lee, Z. Szekanecz, O. Neira, C. Hammond, B. Vlahos, A. Szumski, A.S. Koenig, S. Kotak, Ann Rheum Dis, 1/9/2012
• RADIUS: Characterization of physician and patient global assessments in patients with rheumatoid arthritis
  J. Markenson, A. Koenig, J.-Y. Feng, S. Chaudhari, D.J. Zack, D. Collier, A. Weaver, Ann Rheum Dis, 1/9/2012
• Impact of etanercept therapy on disease activity and health-related quality of life of a moderate rheumatoid arthritis patient population from a national British obser...
  S. Kotak, J. Mardekian, N. Horowicz-Mehler, A. Shah, A. Burgess, J. Kim, E. Gemmen, H. Boyd, A. Koenig, Ann Rheum Dis, 1/8/2012
• Collier Remission in patients with rheumatoid arthritis treated with etanercept (with and without methotrexate) in routine clinical practice as compared to a clinical ...
  E.C. Keystone, G.W. Cannon, B.C. Wang, G.S. Park, A. Koenig, D.H. Collier, Ann Rheum Dis, 1/8/2012
• Predictors of loss of clinical remission with etanercept 50 mg, 25 mg or placebo combined with methotrexate in moderate rheumatoid arthritis patients: results of the p...
  J.S. Smolen, A. Szumski, A.S. Koenig, T.V. Jones, Ann Rheum Dis, 1/8/2012
• Rrelationship between disease duration and response to combination etanercept (etn)-methotrexate (mtx) therapy in subjects with moderately active rheumatoid arthritis
  S. Hall, A. Szumski, A. Koenig, T. Jones, Ann Rheum Dis, 1/8/2012
• Prospective study of primary biliary cirrhosis associated with systemic sclerosis: analysis of the clinical, biological and microvascular aspects at first follow-up visit
  M. Koenig, J.-L. Senécal, C. Vincent, M.J. Fritzler, M. Poliquin, M. Dominguez, R. Leduc, F. Joyal, Ann Rheum Dis, 1/8/2012
• Join now to see all

Other

• Systemic Sclerosis - a Review 
  Jimenez S, Koenig A
  eMedicine.com
  1/1/2001